1naresh2naresh
Array
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
[41d93747-69d9-498e-aaf2-6a7fd9b8d3e3] => Array
(
[runtime-id] => 41d93747-69d9-498e-aaf2-6a7fd9b8d3e3
[type] => toll-free-key
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[5ab2929c-5d68-4f23-9061-544c26aa569f] => Array
(
[runtime-id] => 5ab2929c-5d68-4f23-9061-544c26aa569f
[type] => toll-free-key
)
)
[credentials] => Array
(
[method] => toll-free-key
[value] => tf_ipsecsha;5a456c364e25284e39929c4c9e23c90131fc8a86
)
)
)
1naresh2nareshArray
(
[urn:ac.highwire.org:guest:identity] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:identity
[type] => guest
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[urn:ac.highwire.org:guest:privilege] => Array
(
[runtime-id] => urn:ac.highwire.org:guest:privilege
[type] => privilege-set
[privilege-set] => GUEST
)
)
[credentials] => Array
(
[method] => guest
)
)
[41d93747-69d9-498e-aaf2-6a7fd9b8d3e3] => Array
(
[runtime-id] => 41d93747-69d9-498e-aaf2-6a7fd9b8d3e3
[type] => toll-free-key
[service-id] => ajnr-ac.highwire.org
[access-type] => Controlled
[privilege] => Array
(
[5ab2929c-5d68-4f23-9061-544c26aa569f] => Array
(
[runtime-id] => 5ab2929c-5d68-4f23-9061-544c26aa569f
[type] => toll-free-key
)
)
[credentials] => Array
(
[method] => toll-free-key
[value] => tf_ipsecsha;5a456c364e25284e39929c4c9e23c90131fc8a86
)
)
)
Table 1: Patient and tumor characteristics
Total Cohort Embo No Embo P Value Total patients 470 174 307 – Total treated meningiomas 504 177 327 – Mean age (range) (yr) 57 (17–90) 56 (17–82) 58 (18–90) .2988 Female (%) 336 (71.5) 116 (66.7) 223 (72.6) .185 Tumor location <.001a Olfactory groove (%) 27 (5.5) 5 (2.9) 22 (6.9) Planum sphenoidale/tuberculum (%) 42 (8.6) 5 (2.9) 37 (11.6) Cavernous sinus (%) 5 (1.0) 0 5 (1.6) Sphenoid wing (%) 66 (13.5) 31 (18.0) 35 (11.0) Suprasellar (%) 2 (0.4) 0 2 (0.6) Convexity (%) 187 (38.2) 65 (37.8) 122 (38.2) Parasagittal (%) 88 (18.0) 41 (23.8) 47 (14.7) Middle cranial fossa (%) 12 (2.4) 2 (1.2) 10 (3.1) Posterior fossa (%) 41 (8.4) 18 (10.5) 24 (7.5) Intraosseous (%) 1 (0.2) 1 (0.6) 0 Intraventricular (%) 9 (1.8) 0 9 (2.8) Cerebellopontine angle (%) 10 (2.0) 4 (2.3) 6 (1.9) Skull base location (%) 164 (33.4) 47 (27.3) 117 (36.7) .036a Max. tumor diameter (mm) (range) 38.7 (5–89) 45.6 (16–89) 34.9 (5–89) <.001a Prior resection (%) 59 (11.9) 11 (6.4) 48 (15.0) .005a Prior radiosurgery (%) 35 (7.0) 11 (6.3) 24 (7.5) .626 Prior radiotherapy (%) 12 (2.4) 5 (2.9) 7 (2.2) .633 WHO grade .807 I 344 (74.8) 121 (75.2) 223 (74.6) II 98 (21.3) 35 (21.7) 63 (21.1) III 18 (3.9) 5 (3.1) 13 (4.3) Brain invasion 108 (21.4) 42 (23.7) 56 (17.1) .773
Note:—Embo indicates embolized group; –, not significant; No Embo, non-embolized group; Max., maximum; WHO, World Health Organization.
↵a Significant difference.